Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy
- 30 November 1997
- Vol. 50 (5) , 747-753
- https://doi.org/10.1016/s0090-4295(97)00326-9
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- A retrospective analysis of the cost effectiveness of treatment with Metastron?? (89Sr-chloride) in patients with prostate cancer metastatic to boneNuclear Medicine Communications, 1994
- A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancerRadiotherapy and Oncology, 1994
- Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Pain management in the patient with prostate cancerCancer, 1993
- What is the cost of radiotherapy?European Journal of Radiology, 1991
- The Cost of Prostatic Cancer in a Defined PopulationScandinavian Journal of Urology and Nephrology, 1989
- Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostateEuropean Journal of Nuclear Medicine and Molecular Imaging, 1986